[1]
Hooks JJ,Moutsopoulos HM,Geis SA,Stahl NI,Decker JL,Notkins AL, Immune interferon in the circulation of patients with autoimmune disease. The New England journal of medicine. 1979 Jul 5 [PubMed PMID: 449915]
[2]
Bennett L,Palucka AK,Arce E,Cantrell V,Borvak J,Banchereau J,Pascual V, Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. The Journal of experimental medicine. 2003 Mar 17 [PubMed PMID: 12642603]
[3]
Petri M,Singh S,Tesfasyone H,Dedrick R,Fry K,Lal P,Williams G,Bauer J,Gregersen P,Behrens T,Baechler E, Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus. 2009 Oct; [PubMed PMID: 19762399]
[4]
Baechler EC,Batliwalla FM,Karypis G,Gaffney PM,Ortmann WA,Espe KJ,Shark KB,Grande WJ,Hughes KM,Kapur V,Gregersen PK,Behrens TW, Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proceedings of the National Academy of Sciences of the United States of America. 2003 Mar 4; [PubMed PMID: 12604793]
[5]
Becker AM,Dao KH,Han BK,Kornu R,Lakhanpal S,Mobley AB,Li QZ,Lian Y,Wu T,Reimold AM,Olsen NJ,Karp DR,Chowdhury FZ,Farrar JD,Satterthwaite AB,Mohan C,Lipsky PE,Wakeland EK,Davis LS, SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature. PloS one. 2013; [PubMed PMID: 23826184]
[6]
Crow MK,Kirou KA,Wohlgemuth J, Microarray analysis of interferon-regulated genes in SLE. Autoimmunity. 2003 Dec; [PubMed PMID: 14984025]
[7]
Landolt-Marticorena C,Bonventi G,Lubovich A,Ferguson C,Unnithan T,Su J,Gladman DD,Urowitz M,Fortin PR,Wither J, Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Annals of the rheumatic diseases. 2009 Sep; [PubMed PMID: 18772188]
[8]
Yao Y,Higgs BW,Morehouse C,de Los Reyes M,Trigona W,Brohawn P,White W,Zhang J,White B,Coyle AJ,Kiener PA,Jallal B, Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus. Human genomics and proteomics : HGP. 2009 Nov 17; [PubMed PMID: 20948567]
[9]
Feng X,Huang J,Liu Y,Xiao L,Wang D,Hua B,Tsao BP,Sun L, Identification of interferon-inducible genes as diagnostic biomarker for systemic lupus erythematosus. Clinical rheumatology. 2015 Jan; [PubMed PMID: 25344775]
[10]
Felten R,Scher F,Sagez F,Chasset F,Arnaud L, Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Drug design, development and therapy. 2019; [PubMed PMID: 31190735]
[11]
Klavdianou K,Lazarini A,Fanouriakis A, Targeted Biologic Therapy for Systemic Lupus Erythematosus: Emerging Pathways and Drug Pipeline. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2020 Jan 30; [PubMed PMID: 32002918]
[12]
Furie R,Khamashta M,Merrill JT,Werth VP,Kalunian K,Brohawn P,Illei GG,Drappa J,Wang L,Yoo S, Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis [PubMed PMID: 28130918]
[13]
Merrill JT,Furie R,Werth VP,Khamashta M,Drappa J,Wang L,Illei G,Tummala R, Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. Lupus science [PubMed PMID: 30588322]
[14]
Morand EF,Furie R,Tanaka Y,Bruce IN,Askanase AD,Richez C,Bae SC,Brohawn PZ,Pineda L,Berglind A,Tummala R, Trial of Anifrolumab in Active Systemic Lupus Erythematosus. The New England journal of medicine. 2020 Jan 16; [PubMed PMID: 31851795]
[15]
Peng L,Oganesyan V,Wu H,Dall'Acqua WF,Damschroder MM, Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody. mAbs. 2015; [PubMed PMID: 25606664]
[16]
Khamashta M,Merrill JT,Werth VP,Furie R,Kalunian K,Illei GG,Drappa J,Wang L,Greth W, Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Annals of the rheumatic diseases. 2016 Nov; [PubMed PMID: 27009916]
[17]
Kalunian KC,Merrill JT,Maciuca R,McBride JM,Townsend MJ,Wei X,Davis JC Jr,Kennedy WP, A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Annals of the rheumatic diseases. 2016 Jan; [PubMed PMID: 26038091]
[18]
Rönnblom L,Leonard D, Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus science [PubMed PMID: 31497305]
[19]
Zharkova O,Celhar T,Cravens PD,Satterthwaite AB,Fairhurst AM,Davis LS, Pathways leading to an immunological disease: systemic lupus erythematosus. Rheumatology (Oxford, England). 2017 Apr 1; [PubMed PMID: 28375453]
[20]
Moulton VR,Suarez-Fueyo A,Meidan E,Li H,Mizui M,Tsokos GC, Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective. Trends in molecular medicine. 2017 Jul; [PubMed PMID: 28623084]
[21]
Casey KA,Guo X,Smith MA,Wang S,Sinibaldi D,Sanjuan MA,Wang L,Illei GG,White WI, Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus science [PubMed PMID: 30538817]
[22]
Tummala R,Rouse T,Berglind A,Santiago L, Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers. Lupus science [PubMed PMID: 29644080]
[23]
Richter WF,Jacobsen B, Subcutaneous absorption of biotherapeutics: knowns and unknowns. Drug metabolism and disposition: the biological fate of chemicals. 2014 Nov; [PubMed PMID: 25100673]
[24]
Yu T,Enioutina EY,Brunner HI,Vinks AA,Sherwin CM, Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus. Clinical pharmacokinetics. 2017 Feb; [PubMed PMID: 27384528]